We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Editas Medicine Inc. received exclusive worldwide rights to new CRISPR IP from the Broad Institute, Harvard University, Massachusetts Institute of Technology, Wageningen University, the University of Iowa, and the University of Tokyo. The deal operates under Broad/Harvard/MIT's inclusive innovation model, which, under certain circumstances, allows the research institutions to license IP outside of Editas' scope to third parties.
Deal Industry
Pharmaceuticals
Biotechnology
Gene Therapy, Cell Therapy
Large Molecule
Deal Status
Final
Deal Type
Alliance
Includes Royalty or Profit Split Information
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?